Platelet function mediates both beneficial and harmful effects on human health, but few genes are known to contribute to variability in this process. We tested association of 2.5 million SNPs with platelet aggregation responses to three agonists (ADP, epinephrine and collagen) in two cohorts of European ancestry (N ≤ 2,753 in the Framingham Heart Study, N ≤ 1,238 in the Genetic Study of Atherosclerosis Risk). We identified associations of seven loci with platelet aggregation near or within GP6 (P = 4.6 × 10 −13 ), PEAR1 (P = 3.4 × 10 −12 ), ADRA2A (P = 3.3 × 10 −11 ), PIK3CG (P = 3.1 × 10 −9 ), JMJD1C (P = 1.6 × 10 −8 ), MRVI1 (P = 2.0 × 10 −8 ) and SHH (P = 4.5 × 10 −8 ). Six of these loci replicated at P < 0.05 in an additional African-American cohort (N ≤ 840 in the Genetic Study of Atherosclerosis Risk). These results provide insights into platelet aggregation pathways and may suggest new antiplatelet therapeutic targets.
Aggregation of blood platelets, a critical physiological response to vessel injury, leads to platelet thrombus formation and preserves vascular integrity. Responses are triggered by shear-stress and receptor agonists including ADP, collagen, epinephrine and thrombin. Aggregation responses are mediated by glycoprotein receptors and intracellular signaling pathways that trigger receptor activation and release of granules and thromboxane, further mediating feedback signaling. Although normal platelet responsiveness maintains homeostasis and promotes wound healing, platelet hyperactivity may promote abnormal thrombosis, and the activation of platelets by plaques is a well-known contributor to acute coronary syndrome or stroke. Thus, several platelet aggregation mechanisms are targets for antiplatelet therapies for the treatment and prevention of cardiovascular disease 1 . Individual differences in antiplatelet responses suggest the presence of genetic variability, but studies to date have mainly focused on candidate genes and have uncovered few consistent, replicated associations 2, 3 .
The heritabilities of aggregation responses were previously established in the Framingham Heart Study (FHS) 4 and the Genetic Study of Atherosclerosis Risk (GS) 5 . Rare platelet-related disorders are known 6 ; however, with the exception of a limited scan in FHS 7 , no previous genome-wide scans have been reported for such aggregation phenotypes. To investigate common genetic influences on platelet response, we combined results from two cohorts' genome-wide association studies (GWAS) for platelet aggregation responses to three agonists: ADP, collagen and epinephrine. Our meta-analysis includes two European-ancestry study populations from the FHS and GS, with participants who were free from symptoms of coronary artery disease and not taking anti-platelet medication. We conducted replication in an African-ancestry cohort that is also part of GS. The aim was to discover and replicate genome-wide significant loci associated with platelet aggregation and provide new insights into platelet aggregation mechanisms and their variability in humans.
The two GS cohorts had a lower mean age, and the GS Africanancestry sample had a higher mean BMI and a higher prevalence of smoking, diabetes and hypertension, than the two Europeanancestry cohorts (Supplementary Table 1 ). There was no evidence for inflation of test statistics for the meta-analyses conducted, with all genomic inflation values (λ) ≤ 1.01. We observed eight distinct platelet-aggregation associations ( Table 1 ) that met quality-control filters and surpassed a genome-wide significance threshold in the meta-analysis (P < 5.0 × 10 −8 ) and for which there was evidence for association in the same direction in both FHS and GS (P < 0.05
Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists l e t t e r s in both cohorts). Three regions were genome-wide significant for association with ADP-induced aggregation (Fig. 1, Supplementary  Fig. 1a -c and Table 1 ): 1q23.1 (PEAR1, rs12566888, P = 3.4 × 10 −12 ), 11p15.4 (MRVI1, rs7940646, P = 2.0 × 10 −8 ) and 7q36.3 (SHH, rs2363910, P = 4.5 × 10 −8 ). The minor allele of the PEAR1 SNP was associated with a decrease in aggregation response, whereas the minor alleles of the MRVI1 and 7q36.3 variants were associated with increased responses ( Table 2 ). All three regions showed evidence for replication (P < 0.05) in the African-ancestry sample based on genotyped SNPs that showed association with the same direction of effect (Table 3 ; PEAR1, rs12041331, P = 5.8 × 10 −9 ; MRVI1, rs1874445, P = 9.9 × 10 −3 ; SHH, rs6943029, P = 2.4 × 10 −3 ). Three additional loci were modestly associated with increased aggregation responses to ADP in the European-ancestry cohort and also showed evidence for association in the Africanancestry cohort at P < 0.05 (Supplementary Table 2 ).
Four regions had genome-wide significant associations for epinephrine-induced platelet aggregation (Fig. 2, Supplementary  Fig. 1d -g and Table 1 ): 10q25.2 (ADRA2A, rs4311994, P = 3.3 × 10 −11 ), 1q23.1 (PEAR1, rs12566888, P = 7.3 × 10 −10 ), 7q22.3 (PIK3CG, rs342286, P = 3.1 × 10 −9 ) and 10q21.2 (JMJD1C, rs10761741, P = 1.6 × 10 −8 ). For the ADRA2A, PEAR1 and PIK3CG regions, the minor alleles were associated with reduced epinephrine-induced aggregation ( Table 2) , whereas the minor allele of the peak SNP nearest JMJD1C was associated with increased aggregation ( Table 2) . Three of the regions showed consistent results in the African-ancestry sample ( Table 3 ; PEAR1, rs12041331, P = 8.3 × 10 −17 ; ADRA2A, rs869244, P = 2.2 × 10 −6 ; JMJD1C, rs2893923, P = 8.8 × 10 −3 ). Four SNPs at 7q22.3 did not meet replication criteria (most significant SNP, rs342296, P = 0.13), though none of these was the peak SNP in meta-analyses of the European-ancestry samples. Eight additional regions showed moderate associations with epinephrine-induced aggregation in both the European-ancestry and African-ancestry samples (Supplementary Table 2) . A single region, 19q13.42 (GP6, rs1671152, European-ancestry P = 4.6 × 10 −13 , Africanancestry P = 0.048), was associated with log 10 collagen lag time response at a genome-wide significant level in FHS with P = 9.1 × 10 −14 ( Supplementary Figs. 1h and 2 and Table 1 ). The peak associated SNP causes a tyrosineto-lysine change at amino acid 323. The strong association of the lysine allele with decreased collagen response (as measured by increased lag time; Table 2 ) observed in FHS was weakly replicated in GS (European ancestry, P = 0.037; African ancestry, P = 0.048). Our first meta-analysis compared collagen doses of 190 μg/ml (in FHS using calf skin-derived collagen) with 2 μg/ml (in GS using equine tendon-derived collagen) because these two amounts provided the Figure 1 Genome-wide association metaanalysis plots for ADP-induced platelet aggregation response after filtering of SNPs for quality control. Colored points are SNPs ± 250 kb from a SNP with association stronger than a P-value threshold as follows: red (P < 5.0 × 10 −8 ), blue (P < 4.0 × 10 −7 ) and orange (P < 4.0 × 10 −6 ). Fig. 3) ; this fact is consistent with the several orders of magnitude higher efficacy of equine-as compared to calf-derived collagen (R.W. Scarpelli, Bio/Data Corporation, personal communication). We additionally analyzed associations of the single FHS dose compared with results from three other doses in GS (1, 5 and 10 μg/ml) but did not find any additional genome-wide significant loci or gain stronger replication evidence for the GP6 locus. Three additional loci with evidence of moderate association in the main meta-analysis for collagen lag time in the European-ancestry sample showed similar association in the African-ancestry sample (Supplementary Table 2 ).
Given that the three platelet function agonists analyzed here target partially overlapping mechanisms of platelet aggregation, we inspected whether significantly associated loci overlapped across agonists. Four regions showed association with aggregation phenotypes in both the European-and African-ancestry samples and showed evidence for platelet responses to two agonists (PEAR1, MRVI1, RGS18 and SVIL regions; Supplementary Table 3) . The top meta-analysis SNP and P value in the European-ancestry sample for the same trait and LD with the selected replication SNP based on HapMap CEU using SNAP 41 . b The analyzed traits indicated by sample size are for FHS: ADP EC50 (n = 2,372), ADP 5 μM (n = 1,803), Epi EC50 (n = 2,364), collagen lag to 190 μg/mL (n = 2,310), for GS: ADP 2 μM (n = 1,110 or n = 788), ADP 10 μM (n = 1,227 or n = 836), Epi 2 μM (n = 1,238 or n = 837) and collagen lag to 2 μg/mL (n = 1,162 or n = 763). c The coded allele is the second allele listed. Multiple SNPs in the gene region indicate replication (P < 0.05 with effect in the same direction) but only the most significant SNP in combined analysis is given. d The β values presented in the table relate directly to the phenotypes presented. Because threshold concentrations (EC 50 traits) are inversely related with maximal aggregation response, the signs of the betas for EC 50 traits were flipped before meta-analysis.
l e t t e r s
Although an understanding of rare disorders of platelet aggregation has emerged 6 , the discovery of common genetic variations contributing to platelet aggregation traits has only been marginally successful, even though these traits are heritable 4, 5 . Prior studies were performed in modest sample sizes, used candidate gene approaches focusing on glycoprotein receptors and often used variable conditions across diseased populations. By adopting a GWAS approach in large cohorts of relatively healthy individuals and by using similar platelet-rich plasma (PRP)-derived aggregation phenotypes, we discovered or replicated strong associations (P = 5.0 × 10 −8 ) for seven distinct loci with platelet aggregation and found suggestive evidence for many additional loci (summarized in Table 4 and Supplementary Table 4 ). The findings for the PEAR1(refs. 8,9), ADRA2A 10, 11 and GP6 (refs. 12,13) regions provide strong replication in a much larger sample than used in previous studies and the associations in the regions of MRVI1, SHH, JMJD1C, and PIK3CG are newly reported here.
Platelet endothelial aggregation receptor-1, encoded by PEAR1, undergoes tyrosine phosphorylation after platelet-platelet contact 14 . A PEAR1 promoter-region variant (rs2768759) was associated with increased aggregation in PRP, most strongly in response to epinephrine, in both pre-and post-aspirin treatment conditions 8 . Recently a candidate gene study found association of PEAR1 SNPs with ADP and collagen responses in 500 whole blood-derived samples and an increase in surface PEAR1 expression upon activation 9 . These candidate gene studies 8, 9 had limited coverage of the PEAR1 region. In our study, the SNPs found previously 8, 9 were not among the strongest associations; instead, the peak associations with ADP and epinephrine response found here were within a relatively conserved region of intron 1 of PEAR1.
Variation in ADRA2A receptor numbers and polymorphisms in ADRA2A that influence epinephrine-induced aggregation in diverse populations were reported nearly 15 years ago 10, 11 . The association of ADRA2A expression with epinephrine response is biologically plausible given that ADRA2A serves as the primary receptor for epinephrine on platelets. Additional reports in small samples have reproduced ADRA2A associations 15 , including recognition of complex population patterns in the region and effects on RNA levels in vitro 16 . Notably, unlike in prior studies focused on the immediate gene region, the peak SNP associations we observed are somewhat distant and were 3′ from the gene (European ancestry, rs4311994, 63 kb from ADRA2A, P = 3.3 × 10 −11 ; African ancestry, rs869244, 70 kb from ADRA2A, P = 2.2 × 10 −6 ), suggesting partial LD with causal variants close to the gene or possible long-range regulatory elements. The association of GP6 variants with collagen lag time is biologically plausible, as GP6 is the primary glycoprotein receptor that mediates collagen responses in platelets. The peak GP6 SNP in FHS, encoding a nonsynonymous variant (T323K), was strongly associated with collagen lag time (rs1671152, P = 9.1 × 10 −14 ). Notably, rs1671152 is in LD with rs1613662 (S219P, HapMap CEU r 2 = 1.0). Both variants have been associated with Figure 2 Genome-wide association metaanalysis plots for epinephrine-induced platelet aggregation response after filtering of SNPs for QC. Colored points are SNPs ± 250 kb from a SNP with association stronger than a P-value threshold as follows: red (P < 5.0 × 10 −8 ), blue (P < 4.0 × 10 −7 ) and orange (P < 4.0 × 10 −6 ). a Indicates the average fold intensity of a representative gene transcript relative to the mean background intensity across stem-cell derived megakaryocytes measured with the Illumina Human WG-6 v2 (n = 4 individuals), further described in Watkins et al. 43 l e t t e r s diminished collagen expression or downstream responses 13, 17 . As multiple GP6 protein isoforms exist that are distinguished by splicing and a frameshift alteration, T323K is alternatively H322A in a shorter isoform. Five nonsynonymous SNPs are in LD, including S219P and T323K and H322A, making it difficult to determine which are functional 13, 17 , although a recent study supports an effect on receptor binding of T323K and H322A within this haplotype 17 . GP6 plays a role in thrombus formation 18 . Notably, two studies recently replicated association of the Pro219-encoding allele with reduced risk for deepvein thrombosis, indicating potential clinical relevance for genetic findings in GP6 (refs. 19,20) . In our study, both T323K and S219P were similarly associated with collagen lag time (European ancestry, P = 4.6 × 10 −13 compared to P = 4.7 × 10 −12 ; African ancestry, P = 0.048 compared to P = 0.08). MRVI1 (also known as IRAG), which showed both ADP-and epinephrine-induced associations ( Table 3 and Supplementary  Table 3 ), has prior evidence of functions in platelet aggregation. MRVI1 is a member of a signaling complex which influences smooth muscle cell relaxation through negative regulation of INP3-induced calcium signaling 21 . In mice, MRVI1 plays a direct role in the inhibition of platelet aggregation and in vivo thrombosis 22 . There is also prior evidence for platelet-related functions for some genes at other new loci we report. In a human heterologous system, SHH + microvesicles induce differentiation along a megakaryocyte lineage, suggesting a link to platelet biology 23 . Polymorphisms near PIK3CG (rs342293) were recently shown to be associated with decreased mean platelet volumes 24 . The SNP rs342286, associated here with epinephrine-induced aggregation (P < 3.1 × 10 −9 ), is in a strong LD (HapMap CEU, r 2 = 0.87) with rs342293. Our finding did not directly replicate in African-Americans (P = 0.13), although the direction of effect was similar. A direct function for PIK3CG in platelet signaling has been demonstrated 25 , making it a putative mediator of the effects observed in our current and a prior study 24 .
We note associations near two genes, MRVI1 and PIK3CG, with prior known platelet functions that are related to intracellular signaling pathways in platelets 21, 22, 24, 25 . When we attempted to replicate regions found to have modest evidence for association (P < 1.0 × 10 −4 in the European-ancestry sample), we found further evidence for regions that encode proteins with known involvement in platelet signaling pathways, including RGS18 (refs. [26] [27] [28] [29] , RAP1B [30] [31] [32] [33] and RAPGEF2 (refs. 34,35) , as well as others with putative platelet functions including ST3GAL4 (refs. 36,37) and PRNP 38, 39 (Supplementary Tables 2 and 4) . Evaluation of prior candidate SNPs and gene regions from the literature indicated evidence consistent with prior studies in the regions of P2RY12, a receptor that mediates ADP responses, TAOK1, previously associated with mean platelet volume 40 , and FCER1G, previously associated with collagen response 9 and here associated with collagen lag time (Supplementary Table 5 ).
Combining our findings with those from prior studies, seven loci are strongly implicated in platelet aggregation, with several more loci having consistent evidence in two or more populations (Supplementary Table 4 ). These additional loci contain genes with compelling biological links to platelet function and warrant further investigation. Known functions of genes at the newly associated loci suggest that in addition to glycoprotein receptors, proteins involved in intracellular signal transduction pathways and platelet homeostasis are also critical to mediating aggregation responses. Some genetics variants identified in our study (for example, GP6) have already been associated with clinically apparent cardiovascular disease. It will be important to conduct further functional and clinical studies to examine the clinically relevant function of genetic variants at these loci and the potential of corresponding proteins as targets for drug treatment, given the central role of platelet function in the etiologies of multiple diseases including thrombosis, myocardial infarction, stroke, wound healing and response to infection.
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